ADMA Biologics (NASDAQ:ADMA) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

ADMA Biologics (NASDAQ:ADMA - Get Free Report) released its earnings results on Monday. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01), Zacks reports. The company had revenue of $117.55 million during the quarter, compared to analysts' expectations of $112.80 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%.

ADMA Biologics Stock Performance

Shares of ADMA Biologics stock traded down $0.77 on Thursday, hitting $16.91. The stock had a trading volume of 3,024,933 shares, compared to its average volume of 3,342,058. ADMA Biologics has a 52-week low of $5.88 and a 52-week high of $23.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The stock has a market cap of $4.00 billion, a price-to-earnings ratio of 60.39 and a beta of 0.75. The company's 50 day moving average price is $16.67 and its 200 day moving average price is $17.96.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Cantor Fitzgerald restated an "overweight" rating and issued a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday. HC Wainwright raised their price target on ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, November 8th. Finally, Raymond James raised their price target on ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a research note on Friday, November 8th.

Remove Ads

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.